Sirolimus

Sirolimus may extend lifespan and notably is one of a handful of substances in NIH's Interventions Testing Program to show longevity benefits in mice. It may slow the progression of numerous diseases linked to the aging process such as:

• Alzheimer’s disease
• Artherosclerosis
• Glaucoma,
• Diabetes
• Chronic kidney disease
• Cancers of various types.

Possible side effects on a low dose anti-aging pulse-dose regimen:

• Mouth ulcers
• Facial acneiform rash
• Stomach upset

Precaution

• Avoid use if one has an active infection or is on other immunosuppressive therapies

Sirolimus inhibits the mammalian target of rapamycin (mTOR), a growth signaling pathway. This induces autophagy, process which degrades and recycle a cell's dysfunctional cellular components, thereby keeping the cell viable and functional. It is crucial for maintaining cellular health by removing damaged organelles, misfolded proteins, and other cellular debris. Sirolimus also inhibits "geroconversion", a process responsible for transforming an aging cell in an arrested state into a senescent cell. Senescent cells have ceased dividing and spew inflammatory factors harming healthy neighboring cells. Sirolimus both slows down the generation of senescent cells, and makes existing senescent cells less harmful by decreasing their pro-inflammatory activity. Through these mechanisms, sirolimus may confer longevity benefits and slow down the progression of multiple age-related diseases.

Q. Will taking sirolimus suppress my immune system?

A. Sirolimus is an immunosuppressant at doses used for organ transplants. However, at low pulsatile doses (weekly), sirolimus has distinctly different pharmacological effects and behaves as an immunomodulator. In one study, elderly patients who had been on a sirolimus anti-aging dose regimen had a better response to the flu vaccine than those who did not use sirolimus. Sirolimus at these doses may also enhance some immune functions such as the body's ability to surveil and neutralize cancerous cells. Out of a surfeit of caution, those with active infections should avoid sirolimus.

IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS

This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for individual patient needs based on a valid prescription and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. These statements have not been evaluated by the FDA.

This compounded preparation:

• Has not been approved by the FDA
• Has not undergone FDA review for safety, effectiveness, or quality
• Is prepared specifically for you based on your prescriber's order
• Individual outcomes may vary

Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.

1. Blagosklonny MV. Geroconversion: irreversible step to cellular senescence. Cell Cycle. 2014;13(23):3628-35. doi: 10.4161/15384101.2014.985507. PMID: 25483060; PMCID: PMC4614001.

2. Cayo A, Segovia R, Venturini W, Moore-Carrasco R, Valenzuela C, Brown N. mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership. Int J Mol Sci. 2021 Jul 29;22(15):8149. doi: 10.3390/ijms22158149.

3. Kaeberlein TL, Green AS, Haddad G, Hudson J, Isman A, Nyquist A, Rosen BS, Suh Y, Zalzala S, Zhang X, Blagosklonny MV, An JY, Kaeberlein M. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. Geroscience. 2023 Oct;45(5):2757-2768. doi: 10.1007/s11357-023 00818-1.

4. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014 Dec 24;6(268):268ra179. doi: 10.1126/scitranslmed.3009892. PMID: 25540326.